NANOVIRICIDES, INC. — SEC Form D Filing
NANOVIRICIDES, INC. filed an SEC Form D on February 25, 2026, reporting $6.00M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- February 25, 2026
- Amount reported
- $6.00M
- Round stage
- Series A
- Industry
- Pharmaceuticals
- Website
- https://www.nanoviricides.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
The company addresses the need for effective antiviral treatments to combat various viral infections and pandemics.
Solution
NanoViricides develops broad-spectrum nanoviricides that can target and dismantle a wide range of viruses, making them versatile in treating multiple diseases.
Why now
With the rising incidence of viral infections and pandemics, there is an urgent need for broad-spectrum antiviral therapies.
Verdict
Investors gravitated towards NanoViricides because the urgency surrounding viral infections was more pronounced than prior funding rounds, not due to a unique technological breakthrough. They were implicitly betting on the continued escalation of global health crises necessitating versatile antiviral solutions. However, the limited upside arises from heightened competition and the potential for regulatory hurdles, which could dampen profitability and impact market share despite the company’s novel approach.
Source: SEC EDGAR Form D filing